Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline

Cornea

Volumn 27, Issue 4, 2008, Pages 446-453

  Aydin, Erdinc ^a   Kivilcim, Muhamet ^a,b   Peyman, Gholam A ^a,b,d   Esfahani, Mohammad Riazi ^a   Kazi, Abdul Ahad ^a   Sanders, Donald R ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d Associated Retina Consultants   (United States)

Author keywords

Angiogenesis; Cornea; Doxycycline; Low molecularweight heparin; Triamcinolone acetonide

Indexed keywords

DOXYCYCLINE; LOW MOLECULAR WEIGHT HEPARIN; SODIUM CHLORIDE; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAUTERIZATION; CONTROL GROUP; CONTROLLED STUDY; CORNEA; CORNEA NEOVASCULARIZATION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HYDROGEN-ION CONCENTRATION; MALE; RATS; RATS, LONG-EVANS; TRIAMCINOLONE ACETONIDE;

EID: 42549131348     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181605ff9     Document Type: Article

References (44)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
2. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110:405-407.
3. Reza Dana M, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
4. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
5. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
6. Lepri A, Benelli U, Bernardini N, et al. Effect of low molecular weight heparan sulfate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol. 1994;10:273-280.
7. Proia AD, Hirakata A, McInnes JS, et al. The effect of angiostatic steroids and B-Cyclodextrin tetradecasulfate on corneal neovascularization in rats. Exp Eye Res. 1993;57:693-698.
8. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531-535.
9. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-540.
10. Haynes WL, Proia AD, Klintworth GK. Effects of inhibitors of arachidonic acid metabolism on corneal neovascularization in rats. Invest Ophthalmol Vis Sci. 1989;30:1588-1593.
11. Verbey NL, van Haeringen NJ, de Jong PT. Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase. Curr Eye Res. 1988;7:361-368.
12. Benelli U, Bocci G, Danesi R, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133-142.
13. Joussen AM, Kruse FE, Volcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999;237:920-927.
14. Benelli U, Lepri A, Del Tacca M, et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther. 1996;12:425-431.
15. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
16. Totan Y, Aydin E, Cekic O, et al. Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr Eye Res. 2001;23:291-297.
17. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthesis. Proc Natl Acad Sci USA. 1996;93:14014-14019.
18. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-321.
19. Ramamurty NS, Vernillo AT, Greenwald RA, et al. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res. 1993;8:1247-1253.
20. Riazi-Esfahani M, Peyman GA, Aydin E, et al. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea. 2006;25:801-805.
21. Li WW, Casey R, Gonzalez EM, et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2898-2905.
22. Klintworth GK. Hypotheses about the pathogenesis of corneal vascularization. In: Klinworth GK, ed. Corneal Angiogenesis: A Comprehensive Critical Review. New York: Springer; 1990:23-29.
23. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol. 1999;46:151-208.
24. Colin S, Jeanny JC, Mascarelli F, et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol. 1999;55:74-82.
25. Vlodavsky I, Ishai-Michaeli R, Mohsen M, et al. Modulation of neovascularization and metastasis by species of heparin. Adv Exp Med Biol. 1992;313:317-327.
26. Folkman J, Weisz PB, Joullie MM, et al. Control of angiogenesis with synthetic heparin substitutes. Science. 1989;243:1490-1493.
27. Folkman J, Langer R, Linhardt RJ, et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983;221:719-725.
28. Benelli U, Bocci G, Danesi R, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133-142.
29. Smorenburg SM, Van Noorden CJF. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93-105.
30. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology. 1986;119:1768-1775.
31. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999;77:465-480.
32. Williamson RA, Martson FAO, Angal S, et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J. 1990;268:267-274.
33. Takigawa M, Nishida Y, Suzuki F, et al. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). Biochem Biophys Res Commun. 1990;171:1264-1271.
34. Johnson MD, Kim HC, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol. 1994;160:194-202.
35. Sipos EP, Tamargo RJ, Weingart JD, et al. Inhibition of tumor angiogenesis. Ann N Y Acad Sci. 1994;732:263-272.
36. Fife RS, Sledge GW Jr. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med. 1995;125:407-411.
37. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703-1709.
38. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res. 1998;12:114-118.
39. Smith GN Jr, Mickler EA, Hasty KA, et al. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999;42:1140-1146.
40. Sorsa T, Ramamurthy NS, Vernillo AT, et al. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J Rheumatol. 1998;25:975-982.
41. Lee CZ, Xu B, Hashimoto T, et al. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35:1715-1719.
42. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391-400.
43. Levi E, Fridman R, Miao H, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996;93:7069-7074.
44. O'Reilly MS,Wiederschain D, Stetler-Stevenson WG, et al. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999;274:29568-29571.